SEC Filings

8-K
MEDTRONIC PLC filed this Form 8-K on 11/21/2017
Entire Document
 


MEDTRONIC PLC
U.S.(1) REVENUE
(Unaudited)
 
 
 
 
 
 
 
ADJUSTED
 
 
 
 
 
 
 
 
ADJUSTED
 
REPORTED
 
REVISED(3)
 
 
 
 
REPORTED
 
REVISED(3)
 
 
(in millions)
FY18
Q2
 
FY17
Q2
 
Reported
Growth
 
FY17
Q2
 
Comparable Growth
 
 
FY18
Q2 YTD
 
FY17
Q2 YTD
 
Reported
Growth
 
FY17
Q2 YTD
 
Growth
Cardiac & Vascular Group
$
1,423

 
$
1,353

 
5
 %
 
$
1,353

 
5
 %
 
 
$
2,756

 
$
2,650

 
4
 %
 
$
2,650

 
4
 %
Cardiac Rhythm & Heart Failure
824

 
805

 
2

 
805

 
2

 
 
1,589

 
1,563

 
2

 
1,563

 
2

Coronary & Structural Heart
335

 
289

 
16

 
289

 
16

 
 
651

 
583

 
12

 
583

 
12

Aortic & Peripheral Vascular
264

 
259

 
2

 
259

 
2

 
 
516

 
504

 
2

 
504

 
2

 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 

Minimally Invasive Therapies Group(2)
795

 
1,266

 
(37)
 
834

 
(5
)
 
 
2,040

 
2,501

 
(18)
 
2,069

 
(1
)
Surgical Innovations
522

 
531

 
(2)
 
531

 
(2
)
 
 
1,108

 
1,108

 
 
1,108

 

Respiratory, Gastrointestinal, & Renal
273

 
735

 
(63)
 
303

 
(10
)
 
 
932

 
1,393

 
(33)
 
961

 
(3
)
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 

Restorative Therapies Group
1,258

 
1,261

 

 
1,261

 

 
 
2,479

 
2,468

 

 
2,468

 

Spine
458

 
469

 
(2
)
 
469

 
(2
)
 
 
912

 
921

 
(1
)
 
921

 
(1
)
Brain Therapies
335

 
293

 
14

 
293

 
14

 
 
629

 
571

 
10

 
571

 
10

Specialty Therapies
274

 
285

 
(4
)
 
285

 
(4
)
 
 
554

 
559

 
(1
)
 
559

 
(1
)
Pain Therapies
191

 
214

 
(11
)
 
214

 
(11
)
 
 
384

 
417

 
(8
)
 
417

 
(8
)
 
 
 
 
 

 
 
 

 
 
 
 
 
 
 
 
 
 

Diabetes Group
258

 
272

 
(5
)
 
272

 
(5
)
 
 
501

 
535

 
(6
)
 
535

 
(6
)
 
 
 
 
 

 
 
 

 
 
 
 
 
 
 
 
 
 

TOTAL
$
3,734

 
$
4,152

 
(10
)%
 
$
3,720

 
 %
 
 
$
7,776

 
$
8,154

 
(5
)%
 
$
7,722

 
1
 %

See description of non-GAAP financial measures at the end of the earnings press release.

(1) U.S. includes the United States and U.S. territories.
(2) In the second quarter of fiscal year 2018, the Company realigned its divisions within the Minimally Invasive Therapies Group, which included a movement of revenue from certain product lines within Surgical Innovations to Respiratory Gastrointestinal & Renal. As a result, second quarter fiscal year 2017 results have been recast to adjust for this realignment. Results for the first quarter of fiscal year 2017 and 2018 included within the year-to-date figures herein have not been recast to adjust for this realignment.
(3) Revised revenue excludes revenue related to the divested Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses for the second quarter of fiscal year 2017.


7

X